share_log

S-1: General form for registration of securities under the Securities Act of 1933

S-1: General form for registration of securities under the Securities Act of 1933

S-1：證券上市註冊聲明
美股SEC公告 ·  2024/12/11 20:16

牛牛AI助理已提取核心訊息

Aclarion, a healthcare technology company specializing in chronic low back pain treatments, is facing significant liquidity challenges and going concern issues. The company is actively pursuing additional financing options, including equity offerings and convertible preferred stock issuances, to address these concerns.Aclarion's core product, NOCISCAN, utilizes Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize surgical outcomes for discogenic low back pain patients. A clinical study demonstrated 97% patient improvement when all NOCISCAN-identified painful discs were treated surgically, compared to 54% when not treated. The company received Category III CPT codes in 2021 for reimbursement processes.Despite financial challenges, Aclarion has made progress in its commercialization efforts. The company completed an IPO in April 2022, raising $8.6 million, and entered an equity line agreement with White Lion Capital in October 2023 for up to $10 million. In November 2024, Aclarion issued 560,915 shares to White Lion as commitment shares, with recent securities issuances made under Section 3(a)(9) or 4(a)(2) of the Securities Act and Regulation D.
Aclarion, a healthcare technology company specializing in chronic low back pain treatments, is facing significant liquidity challenges and going concern issues. The company is actively pursuing additional financing options, including equity offerings and convertible preferred stock issuances, to address these concerns.Aclarion's core product, NOCISCAN, utilizes Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize surgical outcomes for discogenic low back pain patients. A clinical study demonstrated 97% patient improvement when all NOCISCAN-identified painful discs were treated surgically, compared to 54% when not treated. The company received Category III CPT codes in 2021 for reimbursement processes.Despite financial challenges, Aclarion has made progress in its commercialization efforts. The company completed an IPO in April 2022, raising $8.6 million, and entered an equity line agreement with White Lion Capital in October 2023 for up to $10 million. In November 2024, Aclarion issued 560,915 shares to White Lion as commitment shares, with recent securities issuances made under Section 3(a)(9) or 4(a)(2) of the Securities Act and Regulation D.
Aclarion是一家專注於慢性下背痛治療的醫療科技公司，目前面臨嚴重的流動性挑戰和持續經營問題。該公司正在積極尋求額外的融資期權，包括股權發行和可轉換優先股的發行，以應對這些問題。Aclarion的核心產品NOCISCAN利用磁共振光譜（MRS）和專有生物標誌物來優化椎間盤源性下背痛患者的手術結果。一項臨床研究表明，當對所有NOCISCAN識別的疼痛椎間盤進行手術治療時，患者改善率達到97%，而未治療時僅爲54%。該公司在2021年獲得了類別III CPt代碼以供報銷程序使用。儘管面臨財務挑戰，Aclarion在商業化努力方面取得了一定進展。該公司在2022年4月完成了首次公開募股，籌集了860萬美元，並於2023年10月與白獅資本簽署了一份高達1000萬美元的股權協定。在2024年11月，Aclarion向白獅發行了560,915股作爲承諾股，最近的證券發行是在證券法第3(a)(9)或第4(a)(2)條款及第D條法規下進行的。
Aclarion是一家專注於慢性下背痛治療的醫療科技公司，目前面臨嚴重的流動性挑戰和持續經營問題。該公司正在積極尋求額外的融資期權，包括股權發行和可轉換優先股的發行，以應對這些問題。Aclarion的核心產品NOCISCAN利用磁共振光譜（MRS）和專有生物標誌物來優化椎間盤源性下背痛患者的手術結果。一項臨床研究表明，當對所有NOCISCAN識別的疼痛椎間盤進行手術治療時，患者改善率達到97%，而未治療時僅爲54%。該公司在2021年獲得了類別III CPt代碼以供報銷程序使用。儘管面臨財務挑戰，Aclarion在商業化努力方面取得了一定進展。該公司在2022年4月完成了首次公開募股，籌集了860萬美元，並於2023年10月與白獅資本簽署了一份高達1000萬美元的股權協定。在2024年11月，Aclarion向白獅發行了560,915股作爲承諾股，最近的證券發行是在證券法第3(a)(9)或第4(a)(2)條款及第D條法規下進行的。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間